Navigation Links
Intra-Cellular Therapies Announces Closing of $60 Million Private Placement and Completion of Reverse Merger
Date:9/3/2013

t and a pre-synaptic partial agonist.  ITI-007 also stimulates phosphorylation of glutamatergic NMDA NR2B receptors in a mesolimbic specific manner.  This regional selectivity in brain areas thought to mediate the efficacy of antipsychotic drugs together with serotonergic, glutamatergic, and dopaminergic interactions is expected to result in antipsychotic efficacy for positive, negative, affective and cognitive symptoms associated with schizophrenia.  The serotonin reuptake inhibition allows for antidepressant efficacy for the treatment of schizoaffective disorder, co-morbid depression, and/or as a stand-alone treatment for major depressive disorder (MDD).  ITI-007 is presently being studied in a randomized, active and placebo controlled Phase II clinical trial as a treatment for schizophrenia.  We believe ITI-007 may also be useful for the treatment of bipolar disorder and other psychiatric and neurodegenerative disorders, particularly behavioral disturbances associated with dementia, autism and other CNS diseases.

ABOUT INTRA-CELLULAR THERAPIES

Intra-Cellular Therapies (ITI) is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative disease and other disorders of the Central Nervous System (CNS).  The Company is studying the efficacy of ITI-007 for the treatment of schizophrenia in a Phase II, multicenter clinical trial.  This Phase II trial follows a favorable Phase I/II study demonstrating the safety and tolerability of ITI-007 across a broad range of doses in patients with stable schizophrenia.  In the Phase I/II trial, exploratory clinical measures revealed signals consistent with antipsychotic efficacy for positive and negative symptoms and antidepressant efficacy for ITI-007.  In February 2011, ITI entered into a collaboration with the Takeda Pharmaceutical Company to develop certain phosphodiesterase 1 (PDE1) inhibitors for the treatment of cognitive deficits in
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
2. Syndax Pharmaceuticals Secures $26.6 Million Series B Financing for Advancement of Epigenetic Therapies for Treatment-Resistant Cancers
3. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
4. Up to Sixty Percent of Surveyed U.S. Managed Care Organization Directors Expect to Cover Key Emerging Therapies for Parkinsons Disease on Their Largest Commercial Plan
5. CSL Biotherapies initiates shipments of its seasonal influenza vaccine to U.S. customers
6. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
7. The Launch of Three New Parkinsons Disease Therapies Through 2015 Will Help Offset Market Losses Resulting from the Growing Impact of Generics
8. Statins Market to 2018 - Weak Product Pipeline and Shift of Focus towards Combination Therapies will Lead to Erosion of Brand Share
9. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
10. In Terms of Effect on Overall Survival, Current and Emerging Therapies Have No Advantage Over Avastin/FOLFIRI in the Treatment of Second-Line Metastatic Colorectal Cancer, According to Clinical Data and Thought Leader Opinion
11. Tafinlar in Combination with Mekinist and Nivolumab Have Considerable Efficacy and Tolerability Advantages Over Currently Used Therapies for the Treatment of Unresectable Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... REDWOOD CITY, Calif. , May 1, 2015  AcelRx ... company focused on the development and commercialization of innovative ... today announced that Timothy E. Morris , chief ... events.  Details of the events are as follows: ... Tuesday, May 5 Location:  The Omni Berkshire Place, ...
(Date:4/30/2015)... ON , April 30, 2015 /PRNewswire/ - ... specialty pharmaceutical company with a focus on Omega-3 ... announced its operational highlights and financial results for ... dollar amounts referenced herein are in Canadian dollars ... 2014 have been significant, with the right strategic ...
(Date:4/30/2015)... SUNNYVALE, Calif. , April 30, 2015 /PRNewswire/ ... that it has signed an agreement with MIM ... for the TomoTherapy ® and CyberKnife ® ... both Accuray and MIM technology. This is Accuray,s ... to the development of the first iPad-based treatment ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2Pivotal Therapeutics Announces 2014 Financial Results 2Pivotal Therapeutics Announces 2014 Financial Results 3Pivotal Therapeutics Announces 2014 Financial Results 4Pivotal Therapeutics Announces 2014 Financial Results 5Pivotal Therapeutics Announces 2014 Financial Results 6Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 2Accuray Signs Agreement with MIM Software Inc. to Develop Adaptive Therapy Software 3
... , , ... SILVER SPRING, Md. , Jan. 18 The ... a counterfeit and potentially harmful version of Alli 60 mg ... ) , Preliminary laboratory tests conducted by GlaxoSmithKline (GSK) -- ...
... , Kidney Care Partners, Members Provide Dialysis Equipment, ... Access to Life-Saving Treatment , PORT-AU-PRINCE, Haiti ... an earthquake that has devastated this Caribbean country, ... of millions of dollars as well as dialysis equipment, medications, ...
Cached Medicine Technology:FDA Warns Consumers about Counterfeit Alli 2FDA Warns Consumers about Counterfeit Alli 3U.S. Kidney Dialysis Community Responds to Haiti's Emergency Plea for Life-Saving Dialysis Care 2U.S. Kidney Dialysis Community Responds to Haiti's Emergency Plea for Life-Saving Dialysis Care 3
(Date:5/2/2015)... As one of only 30 Illinois ... and Health Achievement and Recognition Program (SHARP) certification, ... by the Illinois Department of Labor to host this ... SHARP certification by the Occupational Safety and Health Administration’s ... continued to meet or exceed all of the necessary ...
(Date:5/2/2015)... Vancouver fencing company, QS Fencing, has recently announced that its ... related to their questions on railings and gates. Many people ... and patios. While that seems like an easy task, there ... rolls up their sleeve to start working. One of the ... gate that matches it. , Instead of spending hours worrying ...
(Date:5/2/2015)... ProText Kinetic 2 is a set of typography ... X. ProText Kinetic 2 features 40 animation presets ... X . Easily create interactive text videos without having ... Kinetic 2. , Using ProText Kinetic is as easy as ... presets in the FCPX timeline. Playback the default animation ...
(Date:5/2/2015)... 2015 We are pleased to announce ... Center as one of the Top Workplaces of 2015. ... addiction treatment field for their ethics and standards of ... to continue their educational efforts. The Delray Recovery Center ... forgetting their purpose – to help individuals heal from ...
(Date:5/2/2015)... On Tuesday April 7th, the patient ... to celebrate improvements in patient care. In 2014 the ... had zero acquired ventilator associated infections, zero central line ... was also recently named a Top Performer by the ... credited the teamwork of staff from all departments involved ...
Breaking Medicine News(10 mins):Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 2Health News:Essentra Specialty Tapes is Selected to Host Gov. Rauner and the Workers' Memorial Day Celebration 3Health News:Professional Staff at QS Fencing Company Now Provides Advice on Railings and Gates 2Health News:Pixel Film Studios Announced the Release of Protext Kinetic 2 for FPCX. 2Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:East Liverpool City Hospital Celebrates Patient Care Improvements 2
... going blind and not know it. Silently, without symptoms, Glaucoma ... ,January is Glaucoma Awareness Month, and the American Academy ... urges everyone to get a complete eye exam, especially if ... ,* African-Americans older than 40 ,* Hispanics ,* People with ...
... long been associated with an increased risk of injury ... says a recent study// by a University of Missouri, Columbia. ... Vinson, professor of community and family medicine, found that patients ... injured. However, patients who reported better sleep quality in the ...
... New research published in the Jan. 10 issue of ... University chemists// and North Carolina State University toxicologists, finds ... ,This research was based on the ... buckyball-containing amino acids. "Our results confirm that repetitive ...
... new software-based approach to detect osteoporosis while doing routine ... width of a part of the patient`s lower jaw. ... at the University’s School of Dentistry adapted the ‘active ... of Imaging Sciences and use it to automatically detect ...
... younger someone starts drinking alcoholic beverages, the more likely ... to relieve stress when older, a large new study ... among persons who started drinking at 14 or younger ... drinking are already higher than those of other drinkers,” ...
... undergone a hip replacement surgery and is resting comfortably//. ... the Mayo Clinic in Rochester, Minnesota said on its ... of the current president. His surgery came two days ... of former president Gerald Ford, who died Dec 26 ...
Cached Medicine News:Health News:Glaucoma: Silently Stealing Sight from Millions 2Health News:A Study Explores the Medical Potentials of Bucky Amino Acids 2Health News:Youngest Drinkers Likelier to Use Alcohol for Stress Relief as Adults 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: